MXB-22,510

N/A

Report date: 2024/01/24 15:07:22
NME

Base Information

Drug NameMXB-22,510
Drug Alias NameMXB-22,510
ClassificationOther
Mechanisms of ActionEnvelope glycoprotein inhibitors
TargetsEnvelope glycoprotein
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeSinusitisMycoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMaxwell Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesMaxwell Biosciences Inc
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeSinusitisMycoses
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A